CA2014401A1 - Composes antifongiques de type azote, en aerosol - Google Patents

Composes antifongiques de type azote, en aerosol

Info

Publication number: CA2014401A1
Authority: CA; Canada
Prior art keywords: pharmaceutical formulation; microns; formulation according; propellant; active ingredient
Prior art date: 1989-04-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002014401A

Other languages

English (en)

Inventor

Thomas S. C. Orr

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Fisons Ltd

Original Assignee

Fisons Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-04-12

Filing date

1990-04-11

Publication date

1990-10-12

1990-04-11 Application filed by Fisons Ltd filed Critical Fisons Ltd

1990-10-12 Publication of CA2014401A1 publication Critical patent/CA2014401A1/fr

Status Abandoned legal-status Critical Current

Links

KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title claims abstract description 42
229940121375 antifungal agent Drugs 0.000 title claims abstract description 23
230000000843 anti-fungal effect Effects 0.000 title claims abstract description 10
239000004480 active ingredient Substances 0.000 claims abstract description 24
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
239000002245 particle Substances 0.000 claims description 37
239000003380 propellant Substances 0.000 claims description 25
239000000843 powder Substances 0.000 claims description 15
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 2
VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 2
HUADITLKOCMHSB-AVQIMAJZSA-N 2-butan-2-yl-4-[4-[4-[4-[[(2s,4r)-2-(2,4-difluorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3O[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 HUADITLKOCMHSB-AVQIMAJZSA-N 0.000 claims description 2
SODWJACROGQSMM-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalen-1-amine Chemical compound C1CCCC2=C1C=CC=C2N SODWJACROGQSMM-UHFFFAOYSA-N 0.000 claims description 2
239000007864 aqueous solution Substances 0.000 claims description 2
239000007900 aqueous suspension Substances 0.000 claims description 2
229960004022 clotrimazole Drugs 0.000 claims description 2
VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 2
229960003645 econazole nitrate Drugs 0.000 claims description 2
229960004884 fluconazole Drugs 0.000 claims description 2
RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 2
229960004130 itraconazole Drugs 0.000 claims description 2
229960004125 ketoconazole Drugs 0.000 claims description 2
229950005137 saperconazole Drugs 0.000 claims description 2
MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
229960005040 miconazole nitrate Drugs 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 39
238000009472 formulation Methods 0.000 abstract description 14
239000000443 aerosol Substances 0.000 abstract description 11
208000015181 infectious disease Diseases 0.000 abstract description 6
238000011321 prophylaxis Methods 0.000 abstract description 6
239000000725 suspension Substances 0.000 abstract description 5
230000002538 fungal effect Effects 0.000 abstract description 4
238000000034 method Methods 0.000 abstract description 4
230000002685 pulmonary effect Effects 0.000 abstract description 3
239000004094 surface-active agent Substances 0.000 description 16
239000003429 antifungal agent Substances 0.000 description 10
-1 cyclic anhydride Chemical class 0.000 description 9
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 9
235000019404 dichlorodifluoromethane Nutrition 0.000 description 9
239000007788 liquid Substances 0.000 description 9
210000004072 lung Anatomy 0.000 description 8
239000007787 solid Substances 0.000 description 8
239000003814 drug Substances 0.000 description 7
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 6
208000031888 Mycoses Diseases 0.000 description 6
238000011049 filling Methods 0.000 description 6
239000008187 granular material Substances 0.000 description 6
239000008188 pellet Substances 0.000 description 6
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
206010017533 Fungal infection Diseases 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000000600 sorbitol Substances 0.000 description 5
238000011282 treatment Methods 0.000 description 5
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 5
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
201000002909 Aspergillosis Diseases 0.000 description 3
208000036641 Aspergillus infections Diseases 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
206010061598 Immunodeficiency Diseases 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 3
239000002775 capsule Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000000787 lecithin Substances 0.000 description 3
235000010445 lecithin Nutrition 0.000 description 3
229940067606 lecithin Drugs 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
210000002345 respiratory system Anatomy 0.000 description 3
150000003431 steroids Chemical class 0.000 description 3
CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 2
201000007336 Cryptococcosis Diseases 0.000 description 2
241001337994 Cryptococcus <scale insect> Species 0.000 description 2
241000221204 Cryptococcus neoformans Species 0.000 description 2
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
208000037026 Invasive Fungal Infections Diseases 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000004147 Sorbitan trioleate Substances 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
150000001335 aliphatic alkanes Chemical class 0.000 description 2
208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 description 2
125000000129 anionic group Chemical group 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000000227 grinding Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
229920001451 polypropylene glycol Polymers 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000002002 slurry Substances 0.000 description 2
235000019337 sorbitan trioleate Nutrition 0.000 description 2
229960000391 sorbitan trioleate Drugs 0.000 description 2
238000001694 spray drying Methods 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
229940029284 trichlorofluoromethane Drugs 0.000 description 2
SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
BOSAWIQFTJIYIS-UHFFFAOYSA-N 1,1,1-trichloro-2,2,2-trifluoroethane Chemical compound FC(F)(F)C(Cl)(Cl)Cl BOSAWIQFTJIYIS-UHFFFAOYSA-N 0.000 description 1
AJDIZQLSFPQPEY-UHFFFAOYSA-N 1,1,2-Trichlorotrifluoroethane Chemical compound FC(F)(Cl)C(F)(Cl)Cl AJDIZQLSFPQPEY-UHFFFAOYSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical group NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
241000228212 Aspergillus Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
239000004386 Erythritol Substances 0.000 description 1
UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000001348 alkyl chlorides Chemical class 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
239000012491 analyte Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
238000009835 boiling Methods 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000001273 butane Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
239000001527 calcium lactate Substances 0.000 description 1
229960002401 calcium lactate Drugs 0.000 description 1
235000011086 calcium lactate Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
AFYPFACVUDMOHA-UHFFFAOYSA-N chlorotrifluoromethane Chemical compound FC(F)(F)Cl AFYPFACVUDMOHA-UHFFFAOYSA-N 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
208000018631 connective tissue disease Diseases 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
229960000673 dextrose monohydrate Drugs 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 1
229940099364 dichlorofluoromethane Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000007598 dipping method Methods 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical group [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
235000019414 erythritol Nutrition 0.000 description 1
229940009714 erythritol Drugs 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
230000007124 immune defense Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
201000009085 invasive aspergillosis Diseases 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000003801 milling Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical class CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
208000004235 neutropenia Diseases 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
235000021313 oleic acid Nutrition 0.000 description 1
150000002889 oleic acids Chemical class 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000035515 penetration Effects 0.000 description 1
XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
229960004448 pentamidine Drugs 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000000246 remedial effect Effects 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001433 sodium tartrate Substances 0.000 description 1
229960002167 sodium tartrate Drugs 0.000 description 1
235000011004 sodium tartrates Nutrition 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
229960005078 sorbitan sesquioleate Drugs 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
150000003852 triazoles Chemical class 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Otolaryngology (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA002014401A 1989-04-12 1990-04-11 Composes antifongiques de type azote, en aerosol Abandoned CA2014401A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB898908250A GB8908250D0 (en)	1989-04-12	1989-04-12	Formulations
GB89/08250		1989-04-12

Publications (1)

Publication Number	Publication Date
CA2014401A1 true CA2014401A1 (fr)	1990-10-12

Family

ID=10654880

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002014401A Abandoned CA2014401A1 (fr)	1989-04-12	1990-04-11	Composes antifongiques de type azote, en aerosol

Country Status (7)

Country	Link
EP (1)	EP0467916A1 (fr)
JP (1)	JPH04504419A (fr)
CA (1)	CA2014401A1 (fr)
GB (1)	GB8908250D0 (fr)
GR (1)	GR900100280A (fr)
PT (1)	PT93739A (fr)
WO (1)	WO1990011754A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2601973A1 (fr)	2011-12-09	2013-06-12	Laboratoires SMB SA	Formulation de poudre sèche de dérivé d'azole pour inhalation

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0536235T3 (da) *	1990-06-29	1997-04-14	Fisons Plc	Under tryk stående aerosolpræparater
ZA924163B (en) *	1991-06-10	1993-02-24	Schering Corp	Non-chlorofluorocarbon aerosol formulations
IT1253711B (it) *	1991-12-17	1995-08-23	Alfa Wassermann Spa	Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
US7105152B1 (en)	1991-12-18	2006-09-12	3M Innovative Properties Company	Suspension aerosol formulations
US7101534B1 (en)	1991-12-18	2006-09-05	3M Innovative Properties Company	Suspension aerosol formulations
CZ286619B6 (cs) *	1992-03-18	2000-05-17	Janssen Pharmaceutica N. V.	Stereoisomerické formy itrakonazolu a saperkonazolu, způsob jejich výroby, jejich komplexy, způsob výroby těchto komplexů, farmaceutické přípravky a způsob jejich výroby
EP0680324A4 (fr) *	1993-01-27	1996-04-10	Sepracor Inc	Procedes et compositions utilisant du (2r, 4s) itraconazole.
DE4323636A1 (de) *	1993-07-15	1995-01-19	Hoechst Ag	Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
JP2875140B2 (ja) *	1993-08-16	1999-03-24	明治製菓株式会社	抗ｍｒｓａ組成物
NL1006103C2 (nl) *	1997-05-21	1998-11-25	Nutricia Nv	Huidspray op poederbasis.
DE69725476T2 (de)	1997-12-09	2004-07-22	The Goodyear Tire & Rubber Co., Akron	Luftreifen mit einem transponder und einer ringförmigen antenne und verfahren zur herstellung eines derartigen reifens
AU1511399A (en)	1997-12-31	1999-07-19	Choongwae Pharma Corporation	Method and composition of an oral preparation of itraconazole
US6086376A (en) *	1998-01-30	2000-07-11	Rtp Pharma Inc.	Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6932861B2 (en)	2000-11-28	2005-08-23	Fmc Corporation	Edible PGA coating composition
JP2004517127A (ja)	2000-12-21	2004-06-10	ネクターセラピューティックス	ポリエン抗真菌剤の肺送達
GB0208742D0 (en)	2002-04-17	2002-05-29	Bradford Particle Design Ltd	Particulate materials
US7582284B2 (en)	2002-04-17	2009-09-01	Nektar Therapeutics	Particulate materials
WO2006026502A1 (fr) *	2004-08-27	2006-03-09	The Dow Chemical Company	Administration amelioree de compositions medicamenteuses pour le traitement d'infections parfois mortelles
PT2425820E (pt)	2007-02-11	2015-08-04	Map Pharmaceuticals Inc	Método de administração terapêutica de dhe para permitir o rápido alívio das enxaquecas ao mesmo tempo que minimiza o perfil de efeitos secundários
WO2008124131A1 (fr) *	2007-04-05	2008-10-16	The John Hopkins University	Agents antifongiques comme neuroprotecteurs
AU2009236289B2 (en) *	2008-04-15	2014-08-21	Merck Sharp & Dohme Corp.	Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and HPMCAS
WO2014106727A1 (fr)	2013-01-03	2014-07-10	Vectura Limited	Inhalateur et formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1241602A (fr) *	1984-02-23	1988-09-06	Ortho Pharmaceutical Corporation	Solution fongifuge en aerosol
JPH01153634A (ja) *	1987-12-10	1989-06-15	Kyorin Pharmaceut Co Ltd	吸入剤

1989
- 1989-04-12 GB GB898908250A patent/GB8908250D0/en active Pending
1990
- 1990-04-05 JP JP2505638A patent/JPH04504419A/ja active Pending
- 1990-04-05 WO PCT/GB1990/000513 patent/WO1990011754A1/fr not_active Ceased
- 1990-04-05 EP EP90905606A patent/EP0467916A1/fr not_active Withdrawn
- 1990-04-10 GR GR900100280A patent/GR900100280A/el unknown
- 1990-04-11 PT PT93739A patent/PT93739A/pt not_active Application Discontinuation
- 1990-04-11 CA CA002014401A patent/CA2014401A1/fr not_active Abandoned

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2601973A1 (fr)	2011-12-09	2013-06-12	Laboratoires SMB SA	Formulation de poudre sèche de dérivé d'azole pour inhalation
WO2013083776A1 (fr)	2011-12-09	2013-06-13	Laboratoires Smb Sa	Formulation de poudre sèche d'un dérivé d'azole pour inhalation

Also Published As

Publication number	Publication date
PT93739A (pt)	1990-11-20
GB8908250D0 (en)	1989-05-24
JPH04504419A (ja)	1992-08-06
EP0467916A1 (fr)	1992-01-29
WO1990011754A1 (fr)	1990-10-18
GR900100280A (el)	1991-09-27

Publication	Publication Date	Title
US5334374A (en)	1994-08-02	Pharmaceutical compositions containing pentamidine
US5204113A (en)	1993-04-20	Pharmaceutical compositions containing pentamidine
CA2014401A1 (fr)	1990-10-12	Composes antifongiques de type azote, en aerosol
US4405598A (en)	1983-09-20	Composition for treating asthma
BG63906B1 (bg)	2003-06-30	Фармацевтичен аерозолен състав
AU639460B2 (en)	1993-07-29	Macrolides for the treatment of reversible obstructive airways diseases
SK13342003A3 (sk)	2004-08-03	Lekárske aerosólové prípravky
JP2002521424A (ja)	2002-07-16	医薬用エーロゾル製剤
CA2231968A1 (fr)	1999-09-11	Methode de production d'un medicament a base de nicotine
IE872145L (en)	1988-02-11	Pharmaceutical compositions comprising microcapsules.
IE44760B1 (en)	1982-03-24	A novel form of disoduim cromoglycate
WO1996006598A1 (fr)	1996-03-07	Formulations medicamenteuses en aerosol contenant des glycerides polyglycolyses
CA1178891A (fr)	1984-12-04	Melanges a action biologique et sels de composes heterocycliques
US4849427A (en)	1989-07-18	Nedocromil calcium and use thereof in treatment of reversible obstructive airways disease
US5519049A (en)	1996-05-21	Macrolides for the treatment of reversible obstructive airways diseases
WO1994004148A1 (fr)	1994-03-03	Utilisation de composes de la classe des macrolides dans le traitement de maladies entrainant une obstruction reversible des voies aeriennes
RU2098082C1 (ru)	1997-12-10	Аэрозольная лекарственная композиция для ингаляций (варианты)
SU1641192A3 (ru)	1991-04-07	Способ получени кальциевой соли 10-пропил-2,8-бис-(1Н-тетразол-5-ил)-4Н,6Н-бензо(1,2- @ :5,4- @ )дипиран-4,6-диона
JP2007502791A (ja)	2007-02-15	Ｃｇｒｐアンタゴニスト１−〔ｎ２−〔３，５−ジブロモ−ｎ−〔〔４−（３，４−ジヒドロ−２（１ｈ）−オキソキナゾリン−３−イル）−１−ピペリジニル〕カルボニル〕−ｄ−チロシル〕−ｌ−リシル〕−４−（４−ピリジニル）−ピペラジンを含む新規吸入粉末製剤
CA1083963A (fr)	1980-08-19	Utilisation du flunisolide pour le traitement des maladies respiratoires
CA1176171A (fr)	1984-10-16	Compositions renfermant le sel disodique de 1,3-bis(2-carboxychromon-5-yloxy)-propane-2-o1
SE178687C1 (fr)	1962-01-01

Legal Events

Date	Code	Title	Description
1993-10-11	FZDE	Dead